BioCentury | Aug 20, 2020
Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

...auto-injection that only takes three-to-four seconds at home, once a month,” Victor Bulto, head of Novartis Pharma...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...of regulatory affairs, effective March 31. Zuo was head of drug regulatory affairs at the Novartis Pharma...
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...head of the pharma’s European oncology unit. Karsunky is head Latin America and Canada at Novartis Pharma...
BioCentury | Apr 5, 2019
Company News

Novartis, Amgen in legal battle over Aimovig collaboration

...asked the court to invalidate Amgen's termination request. Novartis alleged that Amgen "wants to cut Novartis Pharma...
...in the U.S." and "now wants to keep the Aimovig profits for itself and deprive Novartis Pharma...
BioCentury | Jun 28, 2018
Company News

Management tracks: Arrakis, Astellas

...chief commercial officer. He is succeeded by Dirk Kosche, who was president at the Japanese Novartis Pharma...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cancer

...A. et al. Nat. Commun. ; published online Oct. 24, 2016 doi:10.1038/ncomms13166 CONTACT: Eva Altmann, Novartis Pharma...
BioCentury | Oct 31, 2016
Company News

Management tracks

...Rainer Boehm is retiring as chief commercial and medical affairs officer at the Novartis Pharma AG division...
BioCentury | Jan 24, 2015
Company News

Array acquires BRAF inhibitor from Novartis

Array BioPharma Inc. (NASDAQ:ARRY) surged $2.06 (41%) to $7.11 after gaining worldwide rights to encorafenib ( LGX818 ) from Novartis AG (NYSE:NVS; SIX:NOVN). Array said it will make a "de minimis" upfront payment to Novartis, but the...
BioCentury | Nov 17, 2014
Clinical News

Rivastach Patch rivastigmine regulatory update

...with AD and Parkinson's disease. Ono has co-development and co-commercialization rights in Japan with Novartis' Novartis Pharma...
BioCentury | Jun 23, 2014
Company News

Novartis A pharmaceuticals news

...said that an ongoing, internal review of adverse event reporting practices in the pharma’s Japanese Novartis Pharma...
Items per page:
1 - 10 of 197
BioCentury | Aug 20, 2020
Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

...auto-injection that only takes three-to-four seconds at home, once a month,” Victor Bulto, head of Novartis Pharma...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...of regulatory affairs, effective March 31. Zuo was head of drug regulatory affairs at the Novartis Pharma...
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...head of the pharma’s European oncology unit. Karsunky is head Latin America and Canada at Novartis Pharma...
BioCentury | Apr 5, 2019
Company News

Novartis, Amgen in legal battle over Aimovig collaboration

...asked the court to invalidate Amgen's termination request. Novartis alleged that Amgen "wants to cut Novartis Pharma...
...in the U.S." and "now wants to keep the Aimovig profits for itself and deprive Novartis Pharma...
BioCentury | Jun 28, 2018
Company News

Management tracks: Arrakis, Astellas

...chief commercial officer. He is succeeded by Dirk Kosche, who was president at the Japanese Novartis Pharma...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cancer

...A. et al. Nat. Commun. ; published online Oct. 24, 2016 doi:10.1038/ncomms13166 CONTACT: Eva Altmann, Novartis Pharma...
BioCentury | Oct 31, 2016
Company News

Management tracks

...Rainer Boehm is retiring as chief commercial and medical affairs officer at the Novartis Pharma AG division...
BioCentury | Jan 24, 2015
Company News

Array acquires BRAF inhibitor from Novartis

Array BioPharma Inc. (NASDAQ:ARRY) surged $2.06 (41%) to $7.11 after gaining worldwide rights to encorafenib ( LGX818 ) from Novartis AG (NYSE:NVS; SIX:NOVN). Array said it will make a "de minimis" upfront payment to Novartis, but the...
BioCentury | Nov 17, 2014
Clinical News

Rivastach Patch rivastigmine regulatory update

...with AD and Parkinson's disease. Ono has co-development and co-commercialization rights in Japan with Novartis' Novartis Pharma...
BioCentury | Jun 23, 2014
Company News

Novartis A pharmaceuticals news

...said that an ongoing, internal review of adverse event reporting practices in the pharma’s Japanese Novartis Pharma...
Items per page:
1 - 10 of 197